Trial reportSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2012
Thyrotropin-releasing hormone as a treatment for cancer-related fatigue: a randomized controlled study.
Trial report in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Placebo response in trials of drug treatments for cancer-related fatigue: a systematic review, meta-analysis and meta-regression.BMJ supportive & palliative care · 2020Pooled it
- Pharmacological Interventions for the Management of Cancer-Related Fatigue Among Cancer Survivors: Systematic Review and Meta-Analysis.Integrative cancer therapiesPooled it
- A preliminary proof-of-concept trial on the effects of ketamine on fatigue: a randomized crossover trial.Pharmacological reports : PR · 2026Trial
- Causal relationship between hormone levels and lung cancer: a Mendelian randomization study.Frontiers in endocrinology · 2025Article
- Efficiency of CIN2+ Detection by Thyrotropin-Releasing Hormone (TRH) Site-Specific Methylation.Viruses · 2023Article
- New Efforts to Demonstrate the Successful Use of TRH as a Therapeutic Agent.International journal of molecular sciences · 2023Review
- Review
- Evaluation of the effects of chemotherapy-induced fatigue and pharmacological interventions in multiple mouse behavioral assays.Behavioural brain research · 2019Article
- Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue.Pharmacological research · 2017Article
- Association of thyroid hormone concentrations with quality of life of primary brain tumor patients: a pilot study.Journal of neuro-oncology · 2017Article
- Fatigue in lung cancer patients: symptom burden and management of challenges.Lung Cancer (Auckland, N.Z.) · 2016Review
- Unmet needs of patients with narcolepsy: perspectives on emerging treatment options.Nature and science of sleep · 2015Review
- Cancer-related fatigue: epidemiology, pathogenesis, diagnosis, and treatment.Deutsches Arzteblatt international · 2012Article
- Exploring the Safety, Effectiveness, and Cost-Effectiveness of a Chinese Patent Medicine (Fufang E'jiao Syrup) for Alleviating Cancer-Related Fatigue: A Protocol for a Randomized, Double-Blinded, Placebo-Controlled, Multicenter Trial.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundFatigue is a common and often disabling symptom for cancer patients. To date, no pharmacological interventions have shown reliable efficacy in treatment of cancer-related fatigue (CF). Thyrotropin-releasing hormone (TRH), a key regulator of homeostasis, exerts arousing and analeptic actions in instances of behavioral depression. In the present pilot, randomized, placebo-controlled, crossover study, we investigated the efficacy and safety of TRH as a treatment for CF.
methodsPatients with cancer experiencing significant fatigue without medically reversible causes were enrolled in this study. The primary outcome measure was the visual analog scale for energy (VAS-E) assessed at 3, 7, and 24 h post-study medication administration. Secondary outcome measures included the profile of mood states (POMS) questionnaire, a 6-min walking test, the hospital anxiety and depression scale, the Leeds sleep questionnaire, and assessment of quality of life using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F).
resultsEight patients completed the study. TRH administration was associated with significant improvement in fatigue level as measured by the VAS-E, the fatigue and vigor subscales of the POMS, and the fatigue subscale of FACIT-F (p < 0.05). It was also associated with a positive impact on quality of life. TRH administration was associated with transient increases in blood pressure and heart rate.
conclusionsTRH administration was efficacious, safe, and tolerable in the treatment of CF with a positive impact on quality of life. These results provide a crucial impetus for pursuing TRH therapeutics to treat CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.